Amryt Pharmaceuticals DAC drugs

3 results

  • filsuvez

    (birch triterpenes)
    Amryt Pharmaceuticals DAC
    FILSUVEZ is indicated for treating wounds related to dystrophic and junctional epidermolysis bullosa (EB) in adults and pediatric patients aged 6 months and older.

  • juxtapid

    (lomitapide mesylate)
    Amryt Pharmaceuticals DAC
    JUXTAPID is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments to reduce LDL-C, total cholesterol, apo B, and non-HDL-C in patients with homozygous familial hypercholesterolemia (HoFH). Its safety and effectiveness are not established for other types of hypercholesterolemia.

  • myalept

    (metreleptin)
    Amryt Pharmaceuticals DAC
    MYALEPT (metreleptin) is indicated as an adjunct to diet for replacing leptin to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. It is not indicated for partial lipodystrophy, liver disease, HIV-related lipodystrophy, or metabolic diseases without generalized lipodystrophy.